Plasma biomarkers of Alzheimer's disease in the continuum of dementia with Lewy bodies

Patricia Diaz-Galvan; Scott A. Przybelski; Alicia Algeciras-Schimnich; Dan J. Figdore; Timothy G. Lesnick; Christopher G. Schwarz; Matthew L. Senjem; Jeffrey L. Gunter; Clifford R. Jack; Paul H. Min; Manoj K. Jain; Toji Miyagawa; Leah K. Forsberg; Julie A. Fields; Rodolfo Savica; Jonathan Graff-Radford; Vijay K. Ramanan; David T. Jones; Hugo Botha; Erik K. St Louis; David S. Knopman; Neill R. Graff-Radford; Tanis J. Ferman; Ronald C. Petersen; Val J. Lowe; Bradley F. Boeve; Kejal Kantarci

doi:10.1002/alz.13653

Plasma biomarkers of Alzheimer's disease in the continuum of dementia with Lewy bodies

Patricia Diaz-Galvan, Scott A. Przybelski, Alicia Algeciras-Schimnich, Dan J. Figdore, Timothy G. Lesnick, Christopher G. Schwarz, Matthew L. Senjem, Jeffrey L. Gunter, Clifford R. Jack, Paul H. Min, Manoj K. Jain, Toji Miyagawa, Leah K. Forsberg, Julie A. Fields, Rodolfo Savica, Jonathan Graff-Radford, Vijay K. Ramanan, David T. Jones, Hugo Botha, Erik K. St LouisDavid S. Knopman, Neill R. Graff-Radford, Tanis J. Ferman, Ronald C. Petersen, Val J. Lowe, Bradley F. Boeve, Kejal Kantarci

Research output: Contribution to journal › Article › peer-review

Abstract

INTRODUCTION: Patients with dementia with Lewy bodies (DLB) may have Alzheimers disease (AD) pathology that can be detected by plasma biomarkers. Our objective was to evaluate plasma biomarkers of AD and their association with positron emission tomography (PET) biomarkers of amyloid and tau deposition in the continuum of DLB, starting from prodromal stages of the disease. METHODS: The cohort included patients with isolated rapid eye movement (REM) sleep behavior disorder (iRBD), mild cognitive impairment with Lewy bodies (MCI-LB), or DLB, with a concurrent blood draw and PET scans. RESULTS: Abnormal levels of plasma glial fibrillary acidic protein (GFAP) were found at the prodromal stage of MCI-LB in association with increased amyloid PET. Abnormal levels of plasma phosphorylated tau (p-tau)-181 and neurofilament light (NfL) were found at the DLB stage. Plasma p-tau-181 showed the highest accuracy in detecting abnormal amyloid and tau PET in patients with DLB. DISCUSSION: The range of AD co-pathology can be detected with plasma biomarkers in the DLB continuum, particularly with plasma p-tau-181 and GFAP.

Original language	English (US)
Journal	Alzheimer's and Dementia
DOIs	https://doi.org/10.1002/alz.13653
State	Accepted/In press - 2024

Keywords

Alzheimer's disease
Lewy body
PET biomarkers
REM sleep behavior disorder
mild cognitive impairment
plasma biomarkers

ASJC Scopus subject areas

Epidemiology
Health Policy
Developmental Neuroscience
Clinical Neurology
Geriatrics and Gerontology
Cellular and Molecular Neuroscience
Psychiatry and Mental health

Access to Document

10.1002/alz.13653

Cite this

Diaz-Galvan, P., Przybelski, S. A., Algeciras-Schimnich, A., Figdore, D. J., Lesnick, T. G., Schwarz, C. G., Senjem, M. L., Gunter, J. L., Jack, C. R., Min, P. H., Jain, M. K., Miyagawa, T., Forsberg, L. K., Fields, J. A., Savica, R., Graff-Radford, J., Ramanan, V. K., Jones, D. T., Botha, H., ... Kantarci, K. (Accepted/In press). Plasma biomarkers of Alzheimer's disease in the continuum of dementia with Lewy bodies. Alzheimer's and Dementia. https://doi.org/10.1002/alz.13653

Diaz-Galvan, P, Przybelski, SA, Algeciras-Schimnich, A, Figdore, DJ, Lesnick, TG, Schwarz, CG, Senjem, ML, Gunter, JL, Jack, CR, Min, PH, Jain, MK, Miyagawa, T, Forsberg, LK, Fields, JA , Savica, R , Graff-Radford, J, Ramanan, VK, Jones, DT , Botha, H , St Louis, EK , Knopman, DS , Graff-Radford, NR , Ferman, TJ , Petersen, RC , Lowe, VJ , Boeve, BF & Kantarci, K 2024, 'Plasma biomarkers of Alzheimer's disease in the continuum of dementia with Lewy bodies', Alzheimer's and Dementia. https://doi.org/10.1002/alz.13653

@article{0a59800369d34b189a049be1451cae70,

title = "Plasma biomarkers of Alzheimer's disease in the continuum of dementia with Lewy bodies",

abstract = "INTRODUCTION: Patients with dementia with Lewy bodies (DLB) may have Alzheimers disease (AD) pathology that can be detected by plasma biomarkers. Our objective was to evaluate plasma biomarkers of AD and their association with positron emission tomography (PET) biomarkers of amyloid and tau deposition in the continuum of DLB, starting from prodromal stages of the disease. METHODS: The cohort included patients with isolated rapid eye movement (REM) sleep behavior disorder (iRBD), mild cognitive impairment with Lewy bodies (MCI-LB), or DLB, with a concurrent blood draw and PET scans. RESULTS: Abnormal levels of plasma glial fibrillary acidic protein (GFAP) were found at the prodromal stage of MCI-LB in association with increased amyloid PET. Abnormal levels of plasma phosphorylated tau (p-tau)-181 and neurofilament light (NfL) were found at the DLB stage. Plasma p-tau-181 showed the highest accuracy in detecting abnormal amyloid and tau PET in patients with DLB. DISCUSSION: The range of AD co-pathology can be detected with plasma biomarkers in the DLB continuum, particularly with plasma p-tau-181 and GFAP.",

keywords = "Alzheimer's disease, Lewy body, PET biomarkers, REM sleep behavior disorder, mild cognitive impairment, plasma biomarkers",

author = "Patricia Diaz-Galvan and Przybelski, {Scott A.} and Alicia Algeciras-Schimnich and Figdore, {Dan J.} and Lesnick, {Timothy G.} and Schwarz, {Christopher G.} and Senjem, {Matthew L.} and Gunter, {Jeffrey L.} and Jack, {Clifford R.} and Min, {Paul H.} and Jain, {Manoj K.} and Toji Miyagawa and Forsberg, {Leah K.} and Fields, {Julie A.} and Rodolfo Savica and Jonathan Graff-Radford and Ramanan, {Vijay K.} and Jones, {David T.} and Hugo Botha and {St Louis}, {Erik K.} and Knopman, {David S.} and Graff-Radford, {Neill R.} and Ferman, {Tanis J.} and Petersen, {Ronald C.} and Lowe, {Val J.} and Boeve, {Bradley F.} and Kejal Kantarci",

note = "Publisher Copyright: {\textcopyright} 2024 The Authors. Alzheimer's & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer's Association.",

year = "2024",

doi = "10.1002/alz.13653",

language = "English (US)",

journal = "Alzheimer's and Dementia",

issn = "1552-5260",

publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Plasma biomarkers of Alzheimer's disease in the continuum of dementia with Lewy bodies

AU - Diaz-Galvan, Patricia

AU - Przybelski, Scott A.

AU - Algeciras-Schimnich, Alicia

AU - Figdore, Dan J.

AU - Lesnick, Timothy G.

AU - Schwarz, Christopher G.

AU - Senjem, Matthew L.

AU - Gunter, Jeffrey L.

AU - Jack, Clifford R.

AU - Min, Paul H.

AU - Jain, Manoj K.

AU - Miyagawa, Toji

AU - Forsberg, Leah K.

AU - Fields, Julie A.

AU - Savica, Rodolfo

AU - Graff-Radford, Jonathan

AU - Ramanan, Vijay K.

AU - Jones, David T.

AU - Botha, Hugo

AU - St Louis, Erik K.

AU - Knopman, David S.

AU - Graff-Radford, Neill R.

AU - Ferman, Tanis J.

AU - Petersen, Ronald C.

AU - Lowe, Val J.

AU - Boeve, Bradley F.

AU - Kantarci, Kejal

PY - 2024

Y1 - 2024

N2 - INTRODUCTION: Patients with dementia with Lewy bodies (DLB) may have Alzheimers disease (AD) pathology that can be detected by plasma biomarkers. Our objective was to evaluate plasma biomarkers of AD and their association with positron emission tomography (PET) biomarkers of amyloid and tau deposition in the continuum of DLB, starting from prodromal stages of the disease. METHODS: The cohort included patients with isolated rapid eye movement (REM) sleep behavior disorder (iRBD), mild cognitive impairment with Lewy bodies (MCI-LB), or DLB, with a concurrent blood draw and PET scans. RESULTS: Abnormal levels of plasma glial fibrillary acidic protein (GFAP) were found at the prodromal stage of MCI-LB in association with increased amyloid PET. Abnormal levels of plasma phosphorylated tau (p-tau)-181 and neurofilament light (NfL) were found at the DLB stage. Plasma p-tau-181 showed the highest accuracy in detecting abnormal amyloid and tau PET in patients with DLB. DISCUSSION: The range of AD co-pathology can be detected with plasma biomarkers in the DLB continuum, particularly with plasma p-tau-181 and GFAP.

AB - INTRODUCTION: Patients with dementia with Lewy bodies (DLB) may have Alzheimers disease (AD) pathology that can be detected by plasma biomarkers. Our objective was to evaluate plasma biomarkers of AD and their association with positron emission tomography (PET) biomarkers of amyloid and tau deposition in the continuum of DLB, starting from prodromal stages of the disease. METHODS: The cohort included patients with isolated rapid eye movement (REM) sleep behavior disorder (iRBD), mild cognitive impairment with Lewy bodies (MCI-LB), or DLB, with a concurrent blood draw and PET scans. RESULTS: Abnormal levels of plasma glial fibrillary acidic protein (GFAP) were found at the prodromal stage of MCI-LB in association with increased amyloid PET. Abnormal levels of plasma phosphorylated tau (p-tau)-181 and neurofilament light (NfL) were found at the DLB stage. Plasma p-tau-181 showed the highest accuracy in detecting abnormal amyloid and tau PET in patients with DLB. DISCUSSION: The range of AD co-pathology can be detected with plasma biomarkers in the DLB continuum, particularly with plasma p-tau-181 and GFAP.

KW - Alzheimer's disease

KW - Lewy body

KW - PET biomarkers

KW - REM sleep behavior disorder

KW - mild cognitive impairment

KW - plasma biomarkers

UR - http://www.scopus.com/inward/record.url?scp=85184415949&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85184415949&partnerID=8YFLogxK

U2 - 10.1002/alz.13653

DO - 10.1002/alz.13653

M3 - Article

AN - SCOPUS:85184415949

SN - 1552-5260

JO - Alzheimer's and Dementia

JF - Alzheimer's and Dementia

ER -

Plasma biomarkers of Alzheimer's disease in the continuum of dementia with Lewy bodies

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this